Drug Profile
Research programme: transgene-enabled cell-based cancer therapies - Mesoblast/Precigen Inc/Alaunos Therapeuitcs
Latest Information Update: 31 Jan 2022
Price :
$50
*
At a glance
- Originator Mesoblast; ZIOPHARM Oncology
- Developer Alaunos Therapeutics; Mesoblast; Precigen Inc
- Class Cell therapies; Gene therapies
- Mechanism of Action Cell replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Non-small cell lung cancer
Most Recent Events
- 26 Jan 2022 ZIOPHARM Oncology is now called Alaunos Therapeutics
- 03 Feb 2020 Intrexon Corporation is now called Precigen Inc
- 28 Jul 2018 No recent reports of development identified for research development in Non-small-cell-lung-cancer in USA (Parenteral)